Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.13 per share a year ago ...

Rigel will participate in one-on-one meetings and present a company overview on Wednesday, September 3, at 8:35 a.m. ET. 2025 Wells Fargo Healthcare Conference in Boston, MA Rigel will participate in ...

Shares of Rigel Pharmaceuticals ($RIGL) took a dive this morning, dropping 17% after the South San Francisco-based biotech announced that it is burying a program for ...

Rigel Pharmaceuticals (RIGL) has been beaten down lately with too much selling pressure. While the stock has lost 27% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Eli Lilly is paying Rigel Pharmaceuticals $125 million up front to grab a share in the development of drugs that would give the company a new way to address inflammation in multiple diseases. The ...

Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M ...

Shares of Rigel Pharmaceuticals RIGL have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s ...

Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, ...